Our mission is to empower biotech innovators to streamline protein engineering campaigns, unlocking breakthrough possibilities for healthcare, sustainability, and industrial transformation. Exazyme harnesses cutting-edge artificial intelligence (AI) and machine learning (ML) technologies to revolutionize protein design, setting new standards in efficiency and precision. Our proprietary platform empowers biotech innovators across diverse industries—from pharmaceuticals to industrial and green biotechnology—to achieve their engineering goals with significantly fewer experimental cycles. By integrating state-of-the-art AI, bioinformatics, and proprietary methodologies, Exazyme enables the discovery of superior proteins with unparalleled performance. Traditional protein engineering methods are often constrained by limited data, high experimental costs, and suboptimal exploration of sequence spaces. Exazyme overcomes these limitations by combining robust AI models with prior biological knowledge and expert guidance. Our platform minimizes data requirements while ensuring model reliability and scalability, allowing for the exploration of vast sequence spaces and delivering remarkable performance gains. With Exazyme, protein engineers can reduce experimental efforts by up to 100x compared to standard approaches, drastically accelerating timelines while achieving superior outcomes. Exazyme’s achievements are backed by esteemed investors, including AIX Ventures and Atlantic Labs. Our work is co-financed by the IBB ProFIT program and the European Union’s EFRE program under the project “Protein Design and Molecular Design with Artificial Intelligence” (Application Numbers: 10196523/10196524).
Externer Link zu Exazyme
Max-Urich Straße 3
AI Campus
Berlin, BE 13355, DE
We’re back with another exciting episode of #MachinesAndMolecules! This time, we’re joined by Victor Guallar, an ICREA Professor and group leader of the EAPM at the Barcelona Supercomputing Center as well as CSO and co-founder of Nostrum Biodiscovery. Victor is a leading expert in molecular modeling, enzyme engineering, and drug discovery, with a career spanning academia and industry. In this episode, Victor dives into the power of Monte Carlo simulations in protein design, highlighting their role in tackling complex challenges in biophysics and sustainability. We also discuss how combining simulation-generated data with AI accelerates innovation, and why bridging the gap between academic research and industry needs is crucial for impactful science. Don’t miss this fascinating conversation - watch the full episode on YouTube, Spotify, or your favourite podcast platform. Link in the comments!
This week, Exazyme is proud to be one of the select Innovation Partners at the 4th Applied Biocatalysis & Enzyme Engineering Summit, taking place from December 10–12 in Philadelphia. This leading event brings together experts in enzyme engineering and biocatalysis to explore cutting-edge innovations in sustainable and efficient solutions for drug development and manufacturing. Our CEO, Ingmar Schuster, will take the stage on Thursday, December 12, at 10:35 AM to present “Minimal Regret in Protein Engineering.” He’ll share how Exazyme’s cutting-edge approaches overcome the limitations of traditional methods, driving success in protein design and engineering. We are excited to join other partners, including Scala Biodesign, Twist Bioscience, Codexis, Inc., and Johnson Matthey, in shaping the future of enzyme innovation. Let’s connect at the event or schedule a meeting in advance - reach out to Ingmar directly! #biocatalysis #proteinengineering
Exazyme hat dies direkt geteilt
Tomorrow, I'll be traveling to Abu Dhabi to attend Xpanse. I'm looking forward to seeing you there!
We’re excited to announce that Exazyme has been selected as a finalist at this year's #FallingWalls #ScienceSummit24! Join us this Thursday as our CEO Ingmar Schuster presents how our AI-driven platform is revolutionizing protein engineering, from initial concept and library creation to advanced protein sequence refinement, boosting speed and innovation in the field. The Falling Walls Foundation unites global leaders in science, innovation, and policy to push boundaries in science and society. It’s an unparalleled opportunity to delve into interdisciplinary insights across life sciences, AI, and sustainability, and to connect with leading scientists, CEOs, and policymakers from around the world. You will find us pitching at the Falling Walls Health Solutions slot on Thursday, from 9:30 to 11:00 AM at the Franklin Stage (https://lnkd.in/dXPgD8N3). Connect with us during the event, or join us at the afterparty at the Merantix AI Campus, hosted by K.I.E.Z. Künstliche Intelligenz Entrepreneurship Zentrum. We look forward to meeting and exchanging ideas with you!
In our latest episode of #MachinesAndMolecules, we’re joined by Markus Müller, an expert in biotechnology and bioeconomy and Project Manager at CLIB - Cluster Industrielle Biotechnologie. Markus brings a wealth of experience in connecting research and industry to drive sustainable bioprocess innovation. In this episode, Markus shares how CLIB distinguishes itself as a neutral mediator, supporting collaboration rather than lobbying, and discusses the unique challenges of integrating biotech and AI into established industries. We dive into the transformative role of biotechnology in developing sustainable alternatives to fossil-based products, the bioeconomy’s potential in recycling and waste reduction, and the importance of clear communication with policymakers to foster regulatory support for biotechnological advancements. Catch the full conversation on YouTube, Spotify, and other platforms, and don’t forget to subscribe! Link in the comments below. #biotechnology #bioeconomy #AIbiotech #sustainablebioprocess
Exazyme hat dies direkt geteilt
Exazyme, our K.I.E.Z alumni, won a nobel price ... well almost. Read the whole story 👇🏼 David Baker has been awarded the 2024 Nobel Prize in Chemistry for computational protein design. Baker is a professor of biochemistry, Howard Hughes Medical Institute (HHMI) investigator, and director of the Institute for Protein Design, University of Washington School of Medicine. The prize is shared with Demis Hassabis and John Jumper of Google DeepMind for their contributions to protein structure prediction. And Exazyme has initiated a collaboration with the Baker lab to explore if and how their technologies could be combined to drive further breakthroughs in protein design. Specifically, their tools for inverse folding are used to generate a starting library to explore a diverse range of sequences, while Exazyme's sequence-to-function models are trained on these data to quickly converge on a global fitness optimum in a broad space. What a great success and connection our alumni team has. Congratulations and keep going! Ingmar Schuster Jelena Ivanovska, PhD Philipp Markert AI NATION
We are back with another episode of #MachinesAndMolecules! This time, we welcome Laura Möller, a prominent figure in the venture capital and entrepreneurship scene, focused on artificial intelligence and technology transfer. As the Director of K.I.E.Z. Künstliche Intelligenz Entrepreneurship Zentrum, Laura has over a decade of experience in driving innovation and supporting AI-driven startups within Berlin's tech ecosystem. Together, we explore the unique challenges faced by AI and science-based startups and discuss how KIEZ fosters an environment for success through tailored support and a strong network. Laura shares her vision for bridging the gap between research and commercialization while emphasizing the need to cultivate entrepreneurial skills among researchers early on. Tune in to catch the full conversation on YouTube, Spotify, and other platforms, and make sure to subscribe! Check out the link in the comments below!
Join us at BioTechX Europe in Basel this week, October 9th-10th! We’ll be attending and would love to meet you - schedule a meeting or stop by our booth (S10) in the startup area! We look forward to discussing the latest industry trends and exploring how Exazyme's AI-powered solutions can help tackle your protein engineering challenges! #biotechx #biotechxeurope
This week, we’re excited to welcome a new addition to the Exazyme team! Please join us in welcoming Boris Nowotny, our new Senior Scientist! He will be joining the biochemistry department in order to consult on internal and external projects around AI-assisted development of novel designer proteins! Boris brings extensive proficiency in protein engineering and therapeutic development to our team. His recent work at the Universitätsklinikum Würzburg, Department of Cellular Immunotherapy, focused on engineering and producing antibodies for advanced immunotherapy. With over a decade of experience, Boris has developed profound expertise in antibody engineering, protein expression, purification, and assay development. He holds a Ph.D. in Virology and Molecular Biology from the The Julius Maximilians University of Würzburg, where his research centered on establishing cellular screening assays for antiviral compounds. His extensive academic and industry background includes roles at Abbott, where he specialized in antigen and antibody production for in vitro diagnostics. We’re thrilled about the insights and contributions he’ll bring to our team. Welcome aboard, Boris! #team #exazyme #scientist #proteinengineering #projectmanagement